DEFINIUM THERAPEUTICS INC (DFTX)
Health Care · Biotechnology · NASDAQ
Definium Therapeutics is a clinical-stage biopharma company developing psychedelic-derived medicines, including proprietary LSD and MDMA formulations, for major psychiatric conditions.
What DEFINIUM THERAPEUTICS INC does
Definium Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of psychiatric disorders. The company's lead product candidates include DT120, a pharmaceutically optimized lysergide D-tartrate (LSD), and DT402, an R(-)-MDMA compound. The company is currently conducting Phase 3 clinical trials for DT120 in generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Themes: psychedelic medicine, mental health / psychiatry, clinical-stage drug development
Fundamentals
- Price$44.91 as of 2026-08-21 close
- Market cap$6.0B as of 2026-08-21
- 1-year return+357.3% 2025-08-21 close $9.82 → 2026-08-21 close $44.91
- P/En/a earnings data not available
- ROE-85.2% as of 2026-08-24
- Debt / equity0.04 as of 2026-08-24
- Beta2.24 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How DFTX compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DFTX is in the Health Care Short-term Top 10.
Health Care Short-term Top 10 — since 18 Aug 2026
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
69.5 #9 of 1,704 scored · #5 of 240 in Health Care
Catalysts 90th: analysts have raised their average price target by 12.2% since the prior reading; trend 79th: a "golden cross" — its 50-day average is above its 200-day; weakest is momentum 56th: MACD momentum is negative.
In this list since 18 Aug 2026 — currently 1st in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 3, score 68.2.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How DEFINIUM THERAPEUTICS INC looks technically
DEFINIUM THERAPEUTICS INC (DFTX) is trading 91.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 290 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 91.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +91.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $41.62 | $41.62 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.47 | $23.47 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 40.6201. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 290 trading days ago — a "golden cross", a bullish long-term signal | 290 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control | 34.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.4 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($40.62 to $49.70) — its "stochastic" reading is 47 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 47.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.70 | $49.70 |
|---|---|---|
| From the 52-week high | it is 9.6% below its 52-week high (its highest price of the past year) | -9.6% |
| Above the 52-week low | it is 416.2% above its 52-week low (its lowest price of the past year) | +416.2% |
| Below the 52-week high | it is 9.6% below its highest point of the past year | 9.6% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $86.55 (set on 2021-04-27) | $86.55 |
| Given back of the 52-week move | over the past year its closes ranged ($8.88 to $48.45), and it has given back only a small part of its rise from last year’s low — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $22.73 to $24.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 8.9% |
| From the all-time high | it is 48.1% below its all-time high | -48.1% |
| Nearest price level | it is trading 8.8% below a resistance level at $48.85 — a price it turned at twice since 2026-06-30, most recently on 2026-07-16. Since 2024-08-21 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +8.8% |
| All-time low | its lowest closing price on record is $0.015 (set on 2019-12-17) | $0.015 |
| Above the all-time low | it is 299300.0% above its all-time low | +299,300% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 34th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.76 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.76 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $40.66 and $47.19 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $40.66 – $43.93 – $47.19 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 7.8 daily ranges above its 200-day average price (91.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.65× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 12.2% since the prior reading | +12.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.03 toward buy |
Candlestick patterns
3
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 16.1% above the previous close 7 sessions ago and has not traded back through the level it left behind at 40.91 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +16.1% |
| Gap filled | a 2.1% gap down opened on 2026-08-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -2.75% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.7 percentage points (the stock lost 0.4% while the market gained 2.3%) | -2.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 95.2 percentage points (the stock gained 98.3% while the market gained 3.1%) | +95.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 151.1 percentage points (the stock gained 162.2% while the market gained 11.1%) | +151.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 336.9 percentage points (the stock gained 357.3% while the market gained 20.5%) | +336.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 13.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +11.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 55% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $29.03 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | +54.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $44.12 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +1.8% |
Price levels it has turned at before
DFTX last closed at $44.91 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $48.85 | Resistance | 8.8% above the last close | turned there twice · 2026-06-30 to 2026-07-16 |
| $40.46 | Support | 9.9% below the last close | turned there twice · 2026-07-28 to 2026-08-11 |
| $19.64 | Support | 56.3% below the last close | turned there twice · 2026-03-10 to 2026-03-20 |
| $14.34 | Support | 68.1% below the last close | turned there three times · 2025-10-20 to 2025-12-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $40.62.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $50.03 and $55.85 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $40.62.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Printed a bearish engulfing pair · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 17 analysts
- Mean price target$67.47 range $52.00 – $90.00; median $66.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DFTX
- Consensus EPS estimate-$0.5585 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the clinical success and regulatory approval of lead product candidate DT120.","Operational risks related to the development and potential commercialization of Schedule I controlled substances.","Significant capital requirements and potential liquidity risks associated with debt covenants in the company's loan agreements."]
What changed in the latest 10-Q
AI-assisted comparison of DFTX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Management's Discussion and Analysis of Financial Condition and Results of Operations' changed from 21 (2025-11-06 filing) to 18 (2026-05-07 filing)
- Page number for 'Quantitative and Qualitative Disclosures About Market Risk' changed from 31 (2025-11-06 filing) to 27 (2026-05-07 filing)
- Page number for 'Controls and Procedures' changed from 31 (2025-11-06 filing) to 27 (2026-05-07 filing)
- Page number for 'OTHER INFORMATION' section changed from 32 (2025-11-06 filing) to 28 (2026-05-07 filing)
- Page number for 'Legal Proceedings' changed from 32 (2025-11-06 filing) to 28 (2026-05-07 filing)
- Notes:
- These changes reflect only page number shifts in the table of contents; the underlying content structure remains identical
Risk Factors
- Added:
- Added bullet point about timing of initiation of Phase 3 clinical trial of DT120 ODT in PTSD and protocol for proposed Phase clinical trial in PTSD (filed 2026-05-07)
- Added reference to DT120 and DT402 product candidate names alongside MM120 and MM402 nomenclature (filed 2026-05-07)
- Added explicit reference to qualified healthcare practitioners as 'HCPs' in parenthetical (filed 2026-05-07)
- Removed:
- Removed bullet point regarding 'the impact of adverse global economic conditions, including trade policies, public health crises, geopolitical conflicts, fluctuations in interest rates, supply-chain disruptions and inflation' from its position in the forward-looking statements list (filed 2025-11-06)
- Removed reference to '2024 Annual Report' filed on 'March 6, 2025' (filed 2025-11-06)
- Reworded:
- Changed product candidate references from 'MM120' to 'DT120 (previously referred to as MM120)' (filed 2026-05-07)
- Changed product candidate references from 'MM402, a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine, also referred to as R(-)-MDMA' to 'DT402 (previously referred to as MM402), also referred to as R(-)-MDMA' (filed 2026-05-07)
- Changed 'stock price' to 'stock price' in activist shareholders bullet point (filed 2026-05-07); note: older version states 'share price'
- Changed annual report reference from '2024 Annual Report' filed 'March 6, 2025' to '2025 Annual Report' filed 'February 26, 2026' (filed 2026-05-07)
- Relocated economic conditions bullet point from position after regulatory approvals bullet to later position after eligible patient populations bullet (filed 2026-05-07)
- Changed 'MM120 ODT' references to 'DT120 ODT' in Phase 3 clinical program bullets (filed 2026-05-07)
- Changed 'MM120 product candidate' to 'DT120 product candidate' in reliance bullet (filed 2026-05-07)
- Changed activist shareholders bullet from 'share price' to 'stock price' (filed 2026-05-07)
- Notes:
- Page numbers changed between filings (Risk Factors listed as page 28 in 2026 filing vs. page 32 in 2025 filing), indicating content reorganization
- The newer filing text appears truncated at the end ('The forward'), making full comparison of closing language not assessable
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 5 sells ($3M) — 5 selling insiders
- Last 180 days0 buys · 5 sells ($3M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-25. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DFTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding DFTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 14,250,955
- Reported value $269,343,060
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DFTX had 10,742,085 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DFTX had 7.99% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.59 days to cover at the same settlement.
- Reported short interest (shares) 10,742,085
- Short interest (% of shares outstanding) 7.99%
- Prior settlement (shares) 10,644,685
- Reported change 0.92%
- Days to cover (reported) 6.59
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
DEFINIUM THERAPEUTICS INC is found in…
Frequently asked questions
What does DEFINIUM THERAPEUTICS INC (DFTX) do?
Definium Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of psychiatric disorders. The company's lead product candidates include DT120, a pharmaceutically optimized lysergide D-tartrate (LSD), and DT402, an R(-)-MDMA compound. The company is currently conducting Phase 3 clinical trials for DT120 in generalized anxiety disorder (GAD) and major depressive disorder (MDD).
What sector is DEFINIUM THERAPEUTICS INC (DFTX) in?
DEFINIUM THERAPEUTICS INC (DFTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is DEFINIUM THERAPEUTICS INC (DFTX) overbought or oversold right now?
DEFINIUM THERAPEUTICS INC (DFTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DFTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.